Project Grant R41HL174360
Award Date
9/1/24
Completion Date
8/31/25
Dollars Obligated
$559K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Indiana, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $889,188 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to develop a new oxygen therapy called intravenous oxygen (IVO2) for the early resuscitation of cardiac arrest patients. The IVO2 therapy utilizes pH-responsive polymeric microbubbles to deliver high...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $793,956 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Resuscitation Innovations LLC, doing business as Advancedcpr Solutions LLC, to develop innovations in CPR and aortic occlusion techniques to improve survival rates for patients experiencing refractory cardiac arrest. The project aims to address the significant unmet need, as nearly 750,000 out of the 800,000 annual cardiac arrest cases in the U.S. result in...
This $1,488,899 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the advanced development and validation of two novel therapeutic compounds, YT-002 and YT-004, to preserve myocardial tissue and function following myocardial infarction. The research aims to optimize the drug formulations, conduct detailed pharmacokinetic and pharmacodynamic studies, and perform comprehensive long-term safety...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $317,285 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Rithim Biologics Inc. to develop a novel gene therapy approach to prevent ventricular tachycardia (VT) following a myocardial infarction. The project aims to finalize the development of an epicardial gene painting catheter, verify targeted ventricular gene expression, and evaluate the safety and efficacy of the gene therapy in a porcine...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Novomedix LLC a $306,872 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel oral small molecule therapeutics for the treatment of progressive pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). The goal is to create a safer and more effective therapy compared to the currently approved drugs, which only slow disease progression and have significant side effects. Novomedix will...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $275,739 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to WR Biotech, LLC, a small disadvantaged business. The grant supports research on a novel technique called Improved Synchronization Modulation Electric Field (I-SMEF) to protect donor hearts and improve transplanted heart graft function during cold storage prior to heart transplantation in mice. The I-SMEF technique aims to maintain...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $400,000 Project Grant to Electronic Biosciences, Inc. on Sep 20, 2024. The grant supports the development of an innovative analytical testing device to quantitatively characterize lipoprotein particles in blood. This technology will enable rapid, precise, and cost-effective measurement of lipoprotein size, concentration, and other physical properties, which are...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $298,368 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Link Medical LLC, a for-profit limited liability company located in Chelsea, Michigan. The grant supports the development of a novel catheter-based technology to treat mitral valve regurgitation, a common cardiovascular condition. The project aims to optimize the device design and procedure through bench testing, followed by conducting in vivo...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $595,464 Project Grant to Cerulean Scientific Inc. on September 25, 2024. The funding supports the development and commercialization of Cerulean Scientific's tethered liquid perfluorocarbon (TLP) coating technology for peripheral vascular grafts (PVGs). The key objectives are to evaluate the durability, anti-fouling properties, and thrombogenicity of...